A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2016
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Millennium
- 28 Apr 2016 Pharmacokinetics results (n=43) published in the British Journal of Clinical Pharmacology.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 23 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.